Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 3/2011

01-12-2011

Therapeutic Perspectives in Atopic Dermatitis

Author: Laurent Misery

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2011

Login to get access

Abstract

Therapy of atopic dermatitis should comprise emollients, topical glucocorticosteroids, or calcineurin inhibitors, phototherapies, immunosuppressants like cyclosporin A, and other treatments. All these treatments should be improved, thanks to research. But new therapeutic perspectives should be given by topical anti-inflammatory substances, selective glucocorticoid receptor agonists, probiotics, interferon γ, TNFα inhibitors, inhibition of T cells or B cells, inhibition of IgE binding, and many other possibilities.
Literature
1.
Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P et al (2006) Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 61:969–987PubMedCrossRef
2.
Misery L, Finlay AY, Martin N, Boussetta S, Nguyen C, Myon E et al (2007) Atopic dermatitis: impact on the quality of life of patients and their partners. Dermatology 215:123–129PubMedCrossRef
3.
Misery L (2005) Atopic dermatitis and psychological factors. Ann Dermatol Venereol 132:S112–S115
4.
5.
Kupfer J, Gieler U, Diepgen TL, Fartasch M, Lob-Corzilius T, Ring J et al (2010) Structured education program improves the coping with atopic dermatitis in children and their parents—a multicenter, randomized controlled trial. J Psychosom Res 68:353–358PubMedCrossRef
6.
Staab D, Diepgen TL, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J et al (2006) Age-related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ 332:933–938PubMedCrossRef
7.
Gelbard CM, Hebert AA (2008) New and emerging trends in the treatment of atopic dermatitis. Patient Prefer Adherence 2:387–392PubMed
8.
9.
Elias PM, Wakefield J (2010) Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis. Clinic Rev Allerg Immunol (in this issue)
10.
Grimalt R, Mengeaud V, Cambazard F (2007) The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology 214:61–67PubMedCrossRef
11.
Sugarman J, Parish L (2009) Efficacy of a lipid-based, barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol 8:1106–1111PubMed
12.
Patrizi A, Raone B, Neri I (2009) Atopiclair Expert Opin Pharmacother 10:1223–1230CrossRef
13.
Hachem JP, Roelandt T, Schürer N, Pu X, Fluhr J, Giddelo C et al (2010) Acute acidification of stratum corneum membrane domains using polyhydroxyl acids improves lipid processing and inhibits degradation of corneodesmosomes. J Invest Dermatol 130:500–510PubMedCrossRef
14.
Thaci D, Salgo R (2010) Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol 28:52–56PubMedCrossRef
15.
Stander S, Stander H, Seeliger S, Luger TA, Steinhoff M (2007) Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin. Br J Dermatol 156:1020–1026PubMedCrossRef
16.
Pereira U, Boulais N, Lebonvallet N, Pennec JP, Dorange G, Misery L (2010) Mechanisms of sensory effects of tacrolimus on the skin. Br J Dermatol 163(1):70–77PubMed
17.
van der Aa LB, Heymans HSA, van Aalderen WMC, Sprikkelman AB (2010) Probiotics and prebiotics in atopic dermatitis: review of the theoretical background and clinical evidence. Pediatr Allergy Immunol 21:e355–e367PubMedCrossRef
18.
Schäcke H, Berger M, Rehwinkel H, Asadullah K (2007) Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 275:109–117PubMedCrossRef
19.
Schäcke H, Zollner TM, Döcke WD, Rehwinkel H, Jaroch S, Skuballa W et al (2009) Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol 158:1088–1103PubMedCrossRef
20.
Jang IG, Yang JK, Lee HJ (2000) Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 42:1033–1040PubMedCrossRef
21.
Meagher LJ, Wines NY, Cooper AJ (2002) Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy. Australas J Dermatol 43:247–254PubMedCrossRef
22.
Jacobi A, Antoni C, Manger B, Schuler G, Hertl M (2005) Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 52:522–526PubMedCrossRef
23.
Buka RL, Resh B, Roberts B, Cunningham BB, Friedlander S (2005) Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol 53:358–359PubMedCrossRef
24.
Davaine AC, Saraux A, Prigent S, Kupfer-Bessaguet I, Roswag D, Plantin P et al (2008) Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study. J Eur Acad Dermatol Venereol 22:1471–1477PubMedCrossRef
25.
Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J et al (2007) Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 156:486–491PubMedCrossRef
26.
Dimitroff CJ, Kupper TS, Sackstein R (2003) Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. J Clin Invest 112:1008–1018PubMed
27.
Harper EG, Simpson EL, Takiguchi RH, Boyd MD, Kurtz SE, Bakke AC et al (2008) Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen. J Invest Dermatol 128:1173–1181PubMedCrossRef
28.
Firmin D, Roguedas AM, Lemasson G, Abgrall JF, Misery L (2008) Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects. Dermatology 217:203–206PubMedCrossRef
29.
Simon D, Wittwer J, Kostylina G, Buettiker U, Simon HU, Yawalkar N (2008) Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 122:423–424PubMedCrossRef
30.
Moul DK, Routhouska SB, Robinson MR, Korman NJ (2008) Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 58:984–989PubMedCrossRef
31.
Simon D, Hösli S, Kostylina G, Yawalkar N, Simon HU (2008) Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 121:122–128PubMedCrossRef
32.
33.
Krathen RA, Hsu S (2005) Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 53:338–340PubMedCrossRef
34.
Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S et al (2007) Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 120:1223–1225PubMedCrossRef
35.
Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ (2006) Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54:68–72PubMedCrossRef
36.
Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB (2008) Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 29:530–537PubMedCrossRef
37.
38.
Metadata
Title
Therapeutic Perspectives in Atopic Dermatitis
Author
Laurent Misery
Publication date
01-12-2011
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 3/2011
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-010-8226-y

Other articles of this Issue 3/2011

Clinical Reviews in Allergy & Immunology 3/2011 Go to the issue

ReviewPaper

What is Intrinsic Atopic Dermatitis?

ReviewPaper

Therapeutic Implications of a Barrier-Based Pathogenesis of Atopic Dermatitis

ReviewPaper

Innate Immunity in Atopic Dermatitis

ReviewPaper

A Modular View of Cytokine Networks in Atopic Dermatitis

ReviewPaper

Atopic Dermatitis: New Trends and Perspectives

ReviewPaper

Atopic Dermatitis and the Nervous System
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits